Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells
Open Access
- 26 May 2005
- journal article
- spotlight
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 19 (8), 1306-1311
- https://doi.org/10.1038/sj.leu.2403807
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemiaBlood, 2004
- Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cellsBlood, 2003
- Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rateLeukemia, 2003
- P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As2O3), but are not the main mechanism of As2O3-resistance in acute promyelocytic leukemia cellsLeukemia, 2003
- Retinoic acid resistance in acute promyelocytic leukemiaLeukemia, 2002
- Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemiaBlood, 2002
- Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiersLeukemia, 2002
- All-trans retinoic acid down-regulates prion protein expression independently of granulocyte maturationLeukemia, 2002
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2001
- Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cellsBritish Journal of Cancer, 1999